BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce it has received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical development program for lead product candidate, eftilagimod alpha (efti or IMP321), in metastatic breast cancer (MBC).

RAPT Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2021.

Iterum Therapeutics plc announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, granting the Company’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550.

TRACON Pharmaceuticals (Nasdaq: TCON), today announced that the first patient has been dosed following the approval of the amended ENVASARC protocol by the U.S. Food and Drug Administration (“FDA”).

Selecta Biosciences, Inc. reported financial results for the quarter and full year ended December 31, 2021 and provided a business update.

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submitted a Scientific Advice Briefing Document with the European Medicines Agency (EMA) for QRX003, the Company’s investigational treatment for Netherton Syndrome.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administered antiviral CC-42344 for the treatment of pandemic and seasonal influenza A.

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a research collaboration agreement with Dr. Tore Bengtsson, Professor of the Department of Molec

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), announced today that results from the US Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients were selected for an oral presentation at the Late-Breaking Research session during the American Academy of Dermatology’s (AAD) 2022 Annual Meeting.